Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

T. Y. Kang; L. A. Rybicki; B. J. Bolwell; S. G. Thakkar; S. Brown; R. Dean; M. A. Sekeres; A. Advani; R. Sobecks; M. Kalaycio; B. Pohlman; J. W. Sweetenham

doi:10.1038/sj.bmt.1705849

Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

T. Y. Kang, L. A. Rybicki, B. J. Bolwell, S. G. Thakkar, S. Brown, R. Dean, M. A. Sekeres, A. Advani, R. Sobecks, M. Kalaycio, B. Pohlman, J. W. Sweetenham

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.

Original language	English (US)
Pages (from-to)	973-978
Number of pages	6
Journal	Bone Marrow Transplantation
Volume	40
Issue number	10
DOIs	https://doi.org/10.1038/sj.bmt.1705849
State	Published - Nov 2007
Externally published	Yes

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1705849

Cite this

Kang, T. Y., Rybicki, L. A., Bolwell, B. J., Thakkar, S. G., Brown, S., Dean, R., Sekeres, M. A., Advani, A., Sobecks, R., Kalaycio, M., Pohlman, B., & Sweetenham, J. W. (2007). Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplantation, 40(10), 973-978. https://doi.org/10.1038/sj.bmt.1705849

@article{8b01d91bd7104c49b24bb75106666115,

title = "Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma",

abstract = "Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.",

author = "Kang, {T. Y.} and Rybicki, {L. A.} and Bolwell, {B. J.} and Thakkar, {S. G.} and S. Brown and R. Dean and Sekeres, {M. A.} and A. Advani and R. Sobecks and M. Kalaycio and B. Pohlman and Sweetenham, {J. W.}",

year = "2007",

month = nov,

doi = "10.1038/sj.bmt.1705849",

language = "English (US)",

volume = "40",

pages = "973--978",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

AU - Kang, T. Y.

AU - Rybicki, L. A.

AU - Bolwell, B. J.

AU - Thakkar, S. G.

AU - Brown, S.

AU - Dean, R.

AU - Sekeres, M. A.

AU - Advani, A.

AU - Sobecks, R.

AU - Kalaycio, M.

AU - Pohlman, B.

AU - Sweetenham, J. W.

PY - 2007/11

Y1 - 2007/11

N2 - Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.

AB - Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.

UR - http://www.scopus.com/inward/record.url?scp=35748934779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748934779&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705849

DO - 10.1038/sj.bmt.1705849

M3 - Article

C2 - 17873917

AN - SCOPUS:35748934779

SN - 0268-3369

VL - 40

SP - 973

EP - 978

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 10

ER -

Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this